Philippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic malignancies.
Philippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic malignancies.
<<<
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More